Cargando…
HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies
G-protein coupled receptor 119 (GPR119) has emerged as a novel target for the treatment of type 2 diabetes mellitus. GPR119 is involved in glucose-stimulated insulin secretion (GSIS) from the pancreatic β-cells and intestinal cells. In this study, we identified a novel small-molecule GPR119 agonist,...
Autores principales: | Kim, SoRa, Kim, Dae Hoon, Kim, Young-Seok, Ha, Tae-Young, Yang, Jin, Park, Soo Hyun, Jeong, Kwang Won, Rhee, Jae-Keol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Applied Pharmacology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201229/ https://www.ncbi.nlm.nih.gov/pubmed/25414769 http://dx.doi.org/10.4062/biomolther.2014.035 |
Ejemplares similares
-
In Vivo Efficacy of HD0471953: A Novel GPR119 Agonist for the Treatment of Type 2 Diabetes Mellitus
por: Kim, So Ra, et al.
Publicado: (2013) -
Preclinical Evaluation of In Vitro and In Vivo Antiviral Activities of KCT-01, a New Herbal Formula against Hepatitis B Virus
por: Kim, Hong, et al.
Publicado: (2018) -
Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study
por: Klöppel, Stefan, et al.
Publicado: (2015) -
A Novel Peptide Derived from the Transmembrane Domain of Romo1 Is a Promising Candidate for Sepsis Treatment and Multidrug-Resistant Bacteria
por: You, Deok-Gyun, et al.
Publicado: (2021) -
Gas formation and biological effects of biodegradable magnesium in a preclinical and clinical observation
por: Kim, Yu-Kyoung, et al.
Publicado: (2018)